The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Secondary resection in a general mCRC population with cetuximab-based first-line treatment: Interim analysis of the German noninterventional study ERBITAG.
Friedrich Overkamp
No relevant relationships to disclose
Thomas Goehler
No relevant relationships to disclose
Gernot Reich
No relevant relationships to disclose
Michael Schwerdtfeger
No relevant relationships to disclose
Patrick Stuebs
No relevant relationships to disclose
Karsten G Stenzel
Employment or Leadership Position - Merck Serono
Ulf P Neumann
Research Funding - Merck Serono